HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by de la Hoya, M. Articles by Caldés, T. Search for Related Content PubMed PubMed Citation Articles by de la Hoya, M. Articles by Caldés, T. Related Collections Molecular Diagnostics and Genetics

Denaturing Gradient Gel Electrophoresis-based Analysis of Loss of Heterozygosity Distinguishes Nonobvious, Deleterious BRCA1 Variants from Nonpathogenic Polymorphisms

¹ Laboratory of Molecular Oncology and Departments of
² Immunology and
³ Oncology, San Carlos University Hospital, 28040 Madrid, Spain;
^a address correspondence to this author at: Laboratorio de Oncología Molecular, Planta Baja Sur, Hospital Clinico San Carlos, c/Martin Lagos s/n, 28040 Madrid, Spain

BRCA1 is a tumor suppressor gene (1) responsible for one-half of familial breast/ovarian cancer syndromes and 40% of breast-only cancer syndromes (2)(3). BRCA1 codes for a 220-kDa nuclear phosphoprotein that has been suggested to play a role in cellular processes, including DNA repair and recombination (4)(5), transcriptional regulation (6)(7), and appropriate chromosomal segregation (8). It is unclear which of BRCA1 functions are important for decreasing breast/ovarian cancer susceptibility.

BRCA1 testing and genetic counseling services are offered to families with histories of breast and/or ovarian cancer (9). The available screening methods to detect germ-line BRCA1 mutations are expensive and time consuming because the gene is large, prevalent BRCA1 mutations are not found (except in ethnic communities), and mutations are scattered throughout the coding sequence (10).

Gene screening often detects a BRCA1 variant that does not imply a frameshift or a splicing alteration but represents a missense mutation not previously reported or registered in the Breast Cancer Informative Core Database (11). To address the question of whether these mutations represent new cancer-predisposing mutations or rare polymorphisms, one must consider characteristics such as absence of the variant in a control group of sufficient size, cosegregation with cancer in some families, and occurrence in a highly conserved protein sequence or in a putative functional domain. These considerations imply the study of large-pedigree families, which very often are not available and the conclusions of which are not always compatible with genetic counseling practice. As an indication of these limitations, only BRCA1 missense mutations that abolish the BRCA1 C-terminal transcriptional activity in a transfection assay (12) or disturb the RING-finger domain structure (13) have been defined as cancer-predisposing mutations (. . . [Full Text of this Article]

Acknowledgments

Footnotes

References

The following articles in journals at HighWire Press have cited this article:

				T Caldes, M de la Hoya, A Tosar, S Sulleiro, J Godino, D Ibanez, M Martin, P Perez-Segura, and E Diaz-Rubio A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes J. Med. Genet., August 1, 2002; 39(8): e44 - 44. [Full Text] [PDF]